The new versus the old: local anaesthesia techniques examined

Article

A survey of British Ophthalmologists has found that there is a lower rate of serious complications after cataract surgery if sub–Tenon's, topical and topical–intracameral local anaesthesias are used rather than the "older" retrobulbar and peribulbar techniques.

A survey of British Ophthalmologists has found that there is a lower rate of serious complications after cataract surgery if sub–Tenon's, topical and topical–intracameral local anaesthesias are used rather than the 'older' retrobulbar and peribulbar techniques.

Tom Eke of the Norfolk & Norwich University Hospital and John Thompson from the University of Leicester, UK, conducted a prospective, observational study of routine practice in the UK for 13 months during the 2002 - 2003 period. The study was done through the British Ophthalmic Surveillance Unit (BOSU). Each month BOSU contacted all senior UK ophthalmologists asking for recent cases of 'potentially sight–threatening or life threatening complications of local anaesthesia for cataract surgery'.

The results showed that cataract surgery, conducted within the National Health Service (NHS), comprised 4.1% under general anaesthesia, 92.1% with local anaesthesia without sedation and 2.9% with local anaesthesia and sedation. Approximately 375,000 local anaesthesias were given for cataract surgery during the survey period. Of these, 30.6% used the peribulbar technique, 3.5% retrobulbar, 42.6% sub–Tenon's, 1.7% sub–conjunctival, 9.9% topical and 11% topical–intracameral local anaesthesia.

The largest number of potentially sight–threatening complications were reported in association with the retrobulbar and peribulbar technique. Twenty–six cases of globe penetration or perforation, 16 of which resulted in a poor visual outcome, were reported. Potentially life–threatening complications were reported with all techniques except for topical and intracameral local anaesthesias. Eight neurological complications were reported, seven of which occurred after peribulbar or retrobulbar anaesthesia.

The authors believe that the study demonstrates that newer techniques, such as sub–Tenon's, topical and topical–intracameral anaesthesia, offer a more favourable safety profile than more traditional methods.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.